ClinicalTrials.gg
CompletedNCT03777657Updated Feb 14, 2025Results posted

Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

A Phase 3 interventional study of Tislelizumab and Placebo in Gastric, or Gastroesophageal Junction Adenocarcinoma, sponsored by BeiGene. Completed at 149 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-14.

Sponsored by BeiGene · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
997
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study was designed to compare the efficacy and safety of tislelizumab plus chemotherapy versus placebo plus chemotherapy as the first treatment (first-line) for adults diagnosed with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

02

Conditions studied

  • Gastric, or Gastroesophageal Junction Adenocarcinoma
03

In context

Lead sponsor

BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.

Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Locally advanced unresectable or gastric cancer (GC) or gastroesophageal junction (GEJ) carcinoma and have confirmed adenocarcinoma
  2. No previous systemic therapy for locally advanced unresectable or metastatic gastric/GEJ cancer. NOTE: Participants may have received prior or adjuvant therapy as long as it was completed and have no recurrence or disease progression for at least 6 months.
  3. performance status (ECOG PS) ≤ 1 within 7 days prior to randomization
  4. Adequate organ function ≤ 7 days prior to randomization

Key Exclusion Criteria:

  1. Has squamous cell or undifferentiated or other histological type GC
  2. Active or uncontrolled
  3. Diagnosed with gastric or GEJ adenocarcinoma with positive
  4. Prior therapy with an anti-programmed cell death protein-1 (), anti-programmed cell death protein ligand-1 (PD-L1), anti-programmed cell death protein ligand-2 (PD-L2), or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
997 participants (actual)

Study arms

  • Experimental
    Tislelizumab + Chemotherapy

    Participants received 200 mg of tislelizumab intravenously with investigator's choice of chemotherapy once every 3 weeks for up to six treatment cycles. Chemotherapy consisted of 1000 mg/m² capecitabine twice daily on Days 1-14 and 130 mg/m² oxaliplatin on Day 1, or 800 mg/m² 5-fluorouracil (5-FU) on Days 1-5 and 80 mg/m² cisplatin on Day 1 of each 21-day cycle. Thereafter, participants continued treatment with 200 mg tislelizumab, with optional maintenance capecitabine (only permitted for participants who initially received capecitabine and oxaliplatin) once every 3 weeks until disease progression or unacceptable toxicity.

    Drug: Tislelizumab · Drug: Cisplatin · Drug: Oxaliplatin · Drug: Capecitabine · Drug: 5-Fluorouracil

  • Placebo comparator
    Placebo + Chemotherapy

    Participants received placebo intravenously with investigator's choice of chemotherapy once every 3 weeks for up to six treatment cycles. Chemotherapy consisted of 1000 mg/m² capecitabine twice daily on Days 1-14 and 130 mg/m² oxaliplatin on Day 1, or 800 mg/m² 5-FU on Days 1-5 and 80 mg/m² cisplatin on Day 1 of each 21-day cycle. Thereafter, participants continued treatment with placebo with optional maintenance capecitabine (only permitted for participants who initially received capecitabine and oxaliplatin) once every 3 weeks until disease progression or unacceptable toxicity.

    Drug: Placebo · Drug: Cisplatin · Drug: Oxaliplatin · Drug: Capecitabine · Drug: 5-Fluorouracil

Interventions

  • 200 mg intravenously (IV) on Day 1 of each 21-day cycle

    Also known as: BGB-A317, TEVIMBRA®

  • DrugPlacebo

    Placebo to match tislelizumab IV on Day 1 of each 21-day cycle

  • 80 mg/m² IV on Day 1 of each 21-day cycle

  • 130 mg/m² IV on Day 1 of each 21-day cycle

  • 1000 mg/m² orally twice daily (BD) Days 1 through 14 (14 days total) of each 21-day cycle

  • 800 mg/m²/day IV using continuous infusion on Days 1 to 5 of each 21-day cycle

06

What researchers measure

Primary outcomes

  1. Overall Survival in PD-L1 Positive Participants

    Overall survival (OS) is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.

    Time frame: From randomization up to the primary analysis data cut-off date of 8 October 2021; Median (range) time on follow-up was 11.8 (0.1 - 33.4) months.

  2. Overall Survival in the Intent-to-Treat (ITT) Analysis Set

    Overall survival (OS) is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.

    Time frame: From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.

Secondary outcomes

  1. Progression-free Survival (PFS) in PD-L1 Positive Participants

    Progression-free survival is defined as the time from the date of randomization to the date of the first objectively documented tumor progression assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.

    Time frame: From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.

  2. Overall Response Rate (ORR) in PD-L1 Positive Participants

    ORR is defined as the percentage of participants whose best overall response is complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors v1.1 assessed by the investigator. Investigators conducted assessments of radiological tumor response by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST version 1.1 about every six weeks during the first 48 weeks of the study and every nine weeks thereafter. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits.

    Time frame: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.

  3. Progression-free Survival (PFS) in the ITT Analysis Set

    Progression-free survival is defined as the time from the date of randomization to the date of the first objectively documented tumor progression assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.

    Time frame: From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.

  4. Overall Response Rate (ORR) in the ITT Analysis Set

    ORR is defined as the percentage of participants whose best overall response is complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors v1.1 assessed by the investigator. Investigators conducted assessments of radiological tumor response by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST version 1.1 about every six weeks during the first 48 weeks of the study and every nine weeks thereafter. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits.

    Time frame: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.

  5. Duration of Response (DOR) in PD-L1 Positive Participants

    DOR is defined as the time from the first determination of an objective response assessed by the investigator per RECIST v1.1, until the first documentation of progression or death, whichever occurred first. Progressive disease (PD): At least a 20% increase in the size of target lesions, taking as reference the smallest size on study, with an absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or any new lesions.

    Time frame: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.

  6. Duration of Response in the ITT Analysis Set

    DOR is defined as the time from the first determination of an objective response assessed by the investigator per RECIST v1.1, until the first documentation of progression or death, whichever occurred first. Progressive disease (PD): At least a 20% increase in the size of target lesions, taking as reference the smallest size on study, with an absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or any new lesions.

    Time frame: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.

  7. Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL) and Physical Functioning Scores

    The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed to a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life.

    Time frame: Baseline and Cycles 4 and 6

  8. Change From Baseline in EORTC QLQ-C30 Fatigue Score

    The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed to a 0 to 100 scale via linear transformation. The fatigue symptom scale includes 3 items and ranges from 0 to 100, where higher scores indicate a higher level of symptoms.

    Time frame: Baseline and Cycles 4 and 6

  9. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Gastric Cancer Module QLQ-STO22 (EORTC QLQ-STO22)

    EORTC-QLQ-STO22 is a 22-item questionnaire developed to assess QoL of gastric cancer participants. It consists of 5 multi-item subscales: Dysphagia/odynophagia (4 items), Pain/discomfort (3 items), Dietary restrictions (5 items), Upper gastro-intestinal (GI) symptoms (3 items), Specific emotional problems (3 items) and 4 single items. Each question is answered on a scale from 0 (Not at all) to 4 (Very Much), where lower scores indicate fewer symptoms/better QoL. Raw scores were transformed to a scale from 0 to 100, where lower scores indicate better QoL. The QLQ-STO22 Index score is the mean of the 6 domain scores and 4 single items.

    Time frame: Baseline and Cycles 4 and 6

  10. Change From Baseline in European Quality of Life 5-Dimensions, 5-level (EQ-5D-5L) Visual Analogue Scale (VAS)

    The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.

    Time frame: Baseline and Cycles 4 and 6

  11. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drugs, whether related to study drugs or not. An SAE is any untoward medical occurrence that, at any dose met any of the following criteria: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the Investigator based on medical judgement.

    Time frame: From first dose of study drug to 30 days after last dose or the initiation of a new anticancer therapy, whichever occurred first, up to the end of study; maximum treatment duration was 59.3 months in Tislelizumab and 56.8 months in the Placebo group.

  12. Disease Control Rate in PD-L1 Positive Participants

    Disease Control Rate is defined as the percentage of participants who had confirmed CR, PR, or stable disease (SD) assessed by the investigator and the investigator per RECIST v1.1. Investigators conducted assessments of radiological tumor response by CT or MRI per RECIST version 1.1 about every six weeks during the first 48 weeks of the study and every nine weeks thereafter. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits. SD: Neither sufficient shrinkage in size of lesions to qualify for PR nor sufficient increase to qualify for PD, and no new lesions.

    Time frame: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.

  13. Disease Control Rate in the ITT Analysis Set

    Disease Control Rate is defined as the percentage of participants who had confirmed CR, PR, or stable disease (SD) assessed by the investigator per RECIST v1.1. Investigators conducted assessments of radiological tumor response by CT or MRI per RECIST version 1.1 about every six weeks during the first 48 weeks of the study and every nine weeks thereafter. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits. SD: Neither sufficient shrinkage in size of lesions to qualify for PR nor sufficient increase to qualify for PD, and no new lesions.

    Time frame: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.

  14. Clinical Benefit Rate (CBR) in PD-L1 Positive Participants

    Clinical benefit rate is defined as the percentage of participants who achieved a confirmed complete response, partial response, or durable stable disease assessed by the Investigator per RECIST v1.1. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits. Durable SD: Stable disease for ≥ 24 weeks.

    Time frame: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.

  15. Clinical Benefit Rate (CBR) in the ITT Analysis Set

    Clinical benefit rate is defined as the percentage of participants who achieved a confirmed complete response, partial response, or durable stable disease assessed by the Investigator per RECIST v1.1. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits. Durable SD: Stable disease for ≥ 24 weeks.

    Time frame: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.

  16. Time to Response (TTR) in PD-L1 Positive Participants

    Time to response is defined as the time from randomization to the first determination of an objective response per RECIST version 1.1 as assessed by the investigator.

    Time frame: From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.

  17. Time to Response (TTR) in the ITT Analysis Set

    Time to response is defined as the time from randomization to the first determination of an objective response per RECIST version 1.1 as assessed by the investigator.

    Time frame: From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.

07

Results

Posted Feb 14, 2025

Participant flow

This study was conducted at 141 study centers in 13 countries across Asia, Europe, and North America. Adults with histologically confirmed, locally advanced unresectable or metastatic gastric or gastrooesophageal junction adenocarcinoma and no previous systemic therapy for advanced disease were recruited.

Participant flow — Overall Study
MilestoneTislelizumab + ChemotherapyPlacebo + Chemotherapy
Started501496
Received treatment498494
Completed10
Not completed500496
Withdrew: Death397431
Withdrew: Study closed by sponsor7738
Withdrew: Withdrawal by subject2017
Withdrew: Lost to follow-up610

Outcome measures

PrimaryOverall Survival in PD-L1 Positive Participants

Overall survival (OS) is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.

Time frame:
From randomization up to the primary analysis data cut-off date of 8 October 2021; Median (range) time on follow-up was 11.8 (0.1 - 33.4) months.
Reported as:
Median · months
Overall Survival in PD-L1 Positive Participants
monthsTislelizumab + ChemotherapyPlacebo + Chemotherapy
Overall Survival in PD-L1 Positive Participants17.2 (13.9 to 21.3)12.6 (12.0 to 14.4)
Statistical analysis
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · One-sided Log Rank Test · p = 0.0056 (The superiority boundary at the primary overall survival analysis was predefined using the O'Brien-Fleming boundary approximated using the Hwang-Shih-DeCani spending function at 0.0092.) · Hazard ratio (hr): 0.74 · 95% CI 0.59 to 0.94The stratified hazard ratio and two-sided 95% confidence interval were estimated using a Cox proportional hazard regression model, including treatment arm as a covariate, and region and presence of peritoneal metastasis as strata.
PrimaryOverall Survival in the Intent-to-Treat (ITT) Analysis Set

Overall survival (OS) is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.

Time frame:
From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Reported as:
Median · months
Overall Survival in the Intent-to-Treat (ITT) Analysis Set
monthsTislelizumab + ChemotherapyPlacebo + Chemotherapy
Overall Survival in the Intent-to-Treat (ITT) Analysis Set15.0 (13.6 to 16.5)12.9 (12.1 to 14.1)
Statistical analysis
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · One-Sided Log-Rank Test · p = 0.0011 (The one sided P value boundary for superiority of overall survival in all randomized participants at final analysis was 0.0226 based on 776 actual observed deaths.) · Hazard ratio (hr): 0.80 · 95% CI 0.70 to 0.92The stratified hazard ratio and two-sided 95% confidence interval were estimated using a Cox proportional hazard regression model, including treatment arm as a covariate, and region, PD-L1 expression, and presence of peritoneal metastasis as strata.
SecondaryProgression-free Survival (PFS) in PD-L1 Positive Participants

Progression-free survival is defined as the time from the date of randomization to the date of the first objectively documented tumor progression assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.

Time frame:
From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Reported as:
Median · months
Progression-free Survival (PFS) in PD-L1 Positive Participants
monthsTislelizumab + ChemotherapyPlacebo + Chemotherapy
Progression-free Survival (PFS) in PD-L1 Positive Participants7.2 (5.8 to 8.4)5.9 (5.6 to 7.0)
Statistical analysis
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Hazard ratio (hr): 0.68 · 95% CI 0.56 to 0.83The stratified hazard ratio and two-sided 95% confidence interval were estimated using a Cox proportional hazard regression model, including treatment arm as a covariate, and region and presence of peritoneal metastasis as strata.
SecondaryOverall Response Rate (ORR) in PD-L1 Positive Participants

ORR is defined as the percentage of participants whose best overall response is complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors v1.1 assessed by the investigator. Investigators conducted assessments of radiological tumor response by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST version 1.1 about every six weeks during the first 48 weeks of the study and every nine weeks thereafter. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits.

Time frame:
Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) in PD-L1 Positive Participants
percentage of participantsTislelizumab + ChemotherapyPlacebo + Chemotherapy
Overall Response Rate (ORR) in PD-L1 Positive Participants51.5 (45.4 to 57.5)42.6 (36.7 to 48.8)
Statistical analysis
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Odds ratio (or): 1.45 · 95% CI 1.03 to 2.04Odds ratio between arms weas calculated using the Cochran-Mantel-Haenszel method, stratified by regions (Asia versus Europe/North America) and presence of peritoneal metastasis.
SecondaryProgression-free Survival (PFS) in the ITT Analysis Set

Progression-free survival is defined as the time from the date of randomization to the date of the first objectively documented tumor progression assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.

Time frame:
From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Reported as:
Median · months
Progression-free Survival (PFS) in the ITT Analysis Set
monthsTislelizumab + ChemotherapyPlacebo + Chemotherapy
Progression-free Survival (PFS) in the ITT Analysis Set6.9 (5.7 to 7.2)6.2 (5.6 to 6.9)
Statistical analysis
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Hazard ratio (hr): 0.78 · 95% CI 0.67 to 0.90The stratified hazard ratio and two-sided 95% confidence interval were estimated using a Cox proportional hazard regression model, including treatment arm as a covariate, and region, PD-L1 expression, and presence of peritoneal metastasis as strata.
SecondaryOverall Response Rate (ORR) in the ITT Analysis Set

ORR is defined as the percentage of participants whose best overall response is complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors v1.1 assessed by the investigator. Investigators conducted assessments of radiological tumor response by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST version 1.1 about every six weeks during the first 48 weeks of the study and every nine weeks thereafter. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits.

Time frame:
Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) in the ITT Analysis Set
percentage of participantsTislelizumab + ChemotherapyPlacebo + Chemotherapy
Overall Response Rate (ORR) in the ITT Analysis Set47.3 (42.9 to 51.8)40.5 (36.2 to 45.0)
Statistical analysis
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Odds ratio (or): 1.33 · 95% CI 1.03 to 1.72Odds ratio between arms were calculated using the Cochran-Mantel-Haenszel method, stratified by regions (Asia versus Europe/North America), PD-L1 expression and presence of peritoneal metastasis.
SecondaryDuration of Response (DOR) in PD-L1 Positive Participants

DOR is defined as the time from the first determination of an objective response assessed by the investigator per RECIST v1.1, until the first documentation of progression or death, whichever occurred first. Progressive disease (PD): At least a 20% increase in the size of target lesions, taking as reference the smallest size on study, with an absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or any new lesions.

Time frame:
Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Reported as:
Median · months
Duration of Response (DOR) in PD-L1 Positive Participants
monthsTislelizumab + ChemotherapyPlacebo + Chemotherapy
Duration of Response (DOR) in PD-L1 Positive Participants10.0 (8.2 to 16.8)6.9 (5.7 to 8.5)
SecondaryDuration of Response in the ITT Analysis Set

DOR is defined as the time from the first determination of an objective response assessed by the investigator per RECIST v1.1, until the first documentation of progression or death, whichever occurred first. Progressive disease (PD): At least a 20% increase in the size of target lesions, taking as reference the smallest size on study, with an absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or any new lesions.

Time frame:
Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Reported as:
Median · months
Duration of Response in the ITT Analysis Set
monthsTislelizumab + ChemotherapyPlacebo + Chemotherapy
Duration of Response in the ITT Analysis Set8.6 (7.9 to 11.1)7.2 (6.0 to 8.5)
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL) and Physical Functioning Scores

The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed to a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life.

Time frame:
Baseline and Cycles 4 and 6
Reported as:
Least squares mean · score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL) and Physical Functioning Scores
score on a scaleTislelizumab + ChemotherapyPlacebo + Chemotherapy
Global Health Status/QOL: Cycle 41.35 (-0.24 to 2.94)-0.45 (-2.04 to 1.13)
Global Health Status/QOL: Cycle 60.93 (-0.71 to 2.57)-1.58 (-3.24 to 0.07)
Physical Functioning: Cycle 4-2.47 (-3.77 to -1.18)-3.92 (-5.21 to -2.62)
Physical Functioning: Cycle 6-2.76 (-4.22 to -1.30)-5.22 (-6.69 to -3.75)
Statistical analysis
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Least squares (ls) mean difference: 1.80 · 95% CI -0.33 to 3.94Mixed effect model analysis with QLQ-C30 scores from cycle 1 to 6 as the response variable, and treatment by study visit interaction, baseline mean score and randomization stratification factors as covariates.
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Ls mean difference: 2.52 · 95% CI 0.29 to 4.74Mixed effect model analysis with QLQ-C30 scores from cycle 1 to 6 as the response variable, and treatment by study visit interaction, baseline mean score and randomization stratification factors as covariates.
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Ls mean difference: 1.44 · 95% CI -0.27 to 3.16
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Ls mean difference: 2.46 · 95% CI 0.49 to 4.43Mixed effect model analysis with QLQ-C30 scores from cycle 1 to 6 as the response variable, and treatment by study visit interaction, baseline mean score and randomization stratification factors as covariates.
SecondaryChange From Baseline in EORTC QLQ-C30 Fatigue Score

The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed to a 0 to 100 scale via linear transformation. The fatigue symptom scale includes 3 items and ranges from 0 to 100, where higher scores indicate a higher level of symptoms.

Time frame:
Baseline and Cycles 4 and 6
Reported as:
Least squares mean · score on a scale
Change From Baseline in EORTC QLQ-C30 Fatigue Score
score on a scaleTislelizumab + ChemotherapyPlacebo + Chemotherapy
Cycle 41.75 (-0.09 to 3.60)3.07 (1.23 to 4.91)
Cycle 61.71 (-0.32 to 3.75)4.73 (2.68 to 6.77)
Statistical analysis
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Ls mean difference: -1.32 · 95% CI -3.79 to 1.15Mixed effect model analysis with QLQ-C30 scores from cycle 1 to 6 as the response variable, and treatment by study visit interaction, baseline mean score and randomization stratification factors as covariates.
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Ls mean difference: -3.01 · 95% CI -5.78 to -0.24Mixed effect model analysis with QLQ-C30 scores from cycle 1 to 6 as the response variable, and treatment by study visit interaction, baseline mean score and randomization stratification factors as covariates.
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Gastric Cancer Module QLQ-STO22 (EORTC QLQ-STO22)

EORTC-QLQ-STO22 is a 22-item questionnaire developed to assess QoL of gastric cancer participants. It consists of 5 multi-item subscales: Dysphagia/odynophagia (4 items), Pain/discomfort (3 items), Dietary restrictions (5 items), Upper gastro-intestinal (GI) symptoms (3 items), Specific emotional problems (3 items) and 4 single items. Each question is answered on a scale from 0 (Not at all) to 4 (Very Much), where lower scores indicate fewer symptoms/better QoL. Raw scores were transformed to a scale from 0 to 100, where lower scores indicate better QoL. The QLQ-STO22 Index score is the mean of the 6 domain scores and 4 single items.

Time frame:
Baseline and Cycles 4 and 6
Reported as:
Least squares mean · units on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Gastric Cancer Module QLQ-STO22 (EORTC QLQ-STO22)
units on a scaleTislelizumab + ChemotherapyPlacebo + Chemotherapy
Index Score: Cycle 4-1.71 (-2.77 to -0.66)-0.61 (-1.66 to 0.45)
Index Score: Cycle 6-1.84 (-2.95 to -0.74)-0.22 (-1.34 to 0.89)
Dysphagia/Odynophagia Scale: Cycle 4-2.78 (-3.99 to -1.57)-1.27 (-2.48 to -0.06)
Dysphagia/Odynophagia Scale: Cycle 6-2.79 (-3.93 to -1.64)-2.01 (-3.17 to -0.86)
Pain/Discomfort Scale: Cycle 4-6.88 (-8.39 to -5.36)-4.64 (-6.16 to -3.13)
Pain/Discomfort Scale: Cycle 6-5.97 (-7.56 to -4.38)-4.09 (-5.69 to -2.49)
Dietary Restrictions Scale: Cycle 4-0.31 (-1.75 to 1.12)0.61 (-0.82 to 2.05)
Dietary Restrictions Scale: Cycle 6-0.25 (-1.79 to 1.30)1.08 (-0.48 to 2.63)
Upper Gastro-Intestinal Symptoms: Cycle 4-3.14 (-4.40 to -1.87)-1.54 (-2.80 to -0.28)
Upper Gastro-Intestinal Symptoms: Cycle 6-3.24 (-4.58 to -1.90)-1.49 (-2.84 to -0.14)
Statistical analysis
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Ls mean difference: -1.11 · 95% CI -2.53 to 0.31Mixed effect model analysis with QLQ-STO22 scores from cycle 1 to 6 as the response variable, and treatment by study visit interaction, baseline mean score and randomization stratification factors as covariates.
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Ls mean difference: -1.62 · 95% CI -3.12 to -0.12Mixed effect model analysis with QLQ-STO22 scores from cycle 1 to 6 as the response variable, and treatment by study visit interaction, baseline mean score and randomization stratification factors as covariates.
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Ls mean difference: -1.51 · 95% CI -3.13 to 0.11Mixed effect model analysis with QLQ-STO22 scores from cycle 1 to 6 as the response variable, and treatment by study visit interaction, baseline mean score and randomization stratification factors as covariates.
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Ls mean difference: -0.77 · 95% CI -2.31 to 0.76Mixed effect model analysis with QLQ-STO22 scores from cycle 1 to 6 as the response variable, and treatment by study visit interaction, baseline mean score and randomization stratification factors as covariates.
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Ls mean difference: -2.23 · 95% CI -4.26 to -0.20Mixed effect model analysis with QLQ-STO22 scores from cycle 1 to 6 as the response variable, and treatment by study visit interaction, baseline mean score and randomization stratification factors as covariates.
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Ls mean difference: -1.88 · 95% CI -4.03 to 0.27Mixed effect model analysis with QLQ-STO22 scores from cycle 1 to 6 as the response variable, and treatment by study visit interaction, baseline mean score and randomization stratification factors as covariates.
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Ls mean difference: -0.93 · 95% CI -2.85 to 0.99Mixed effect model analysis with QLQ-STO22 scores from cycle 1 to 6 as the response variable, and treatment by study visit interaction, baseline mean score and randomization stratification factors as covariates.
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Ls mean difference: -1.32 · 95% CI -3.42 to 0.77Mixed effect model analysis with QLQ-STO22 scores from cycle 1 to 6 as the response variable, and treatment by study visit interaction, baseline mean score and randomization stratification factors as covariates.
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Ls mean difference: -1.59 · 95% CI -3.28 to 0.09Mixed effect model analysis with QLQ-STO22 scores from cycle 1 to 6 as the response variable, and treatment by study visit interaction, baseline mean score and randomization stratification factors as covariates.
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Ls mean difference: -1.74 · 95% CI -3.55 to 0.06Mixed effect model analysis with QLQ-STO22 scores from cycle 1 to 6 as the response variable, and treatment by study visit interaction, baseline mean score and randomization stratification factors as covariates.
SecondaryChange From Baseline in European Quality of Life 5-Dimensions, 5-level (EQ-5D-5L) Visual Analogue Scale (VAS)

The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.

Time frame:
Baseline and Cycles 4 and 6
Reported as:
Mean · score on a scale
Change From Baseline in European Quality of Life 5-Dimensions, 5-level (EQ-5D-5L) Visual Analogue Scale (VAS)
score on a scaleTislelizumab + ChemotherapyPlacebo + Chemotherapy
Cycle 42.9 ± 15.620.8 ± 14.91
Cycle 63.0 ± 16.38-0.8 ± 15.17
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drugs, whether related to study drugs or not. An SAE is any untoward medical occurrence that, at any dose met any of the following criteria: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the Investigator based on medical judgement.

Time frame:
From first dose of study drug to 30 days after last dose or the initiation of a new anticancer therapy, whichever occurred first, up to the end of study; maximum treatment duration was 59.3 months in Tislelizumab and 56.8 months in the Placebo group.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsTislelizumab + ChemotherapyPlacebo + Chemotherapy
Any TEAE495486
Any SAE211179
SecondaryDisease Control Rate in PD-L1 Positive Participants

Disease Control Rate is defined as the percentage of participants who had confirmed CR, PR, or stable disease (SD) assessed by the investigator and the investigator per RECIST v1.1. Investigators conducted assessments of radiological tumor response by CT or MRI per RECIST version 1.1 about every six weeks during the first 48 weeks of the study and every nine weeks thereafter. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits. SD: Neither sufficient shrinkage in size of lesions to qualify for PR nor sufficient increase to qualify for PD, and no new lesions.

Time frame:
Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Reported as:
Number · percentage of participants
Disease Control Rate in PD-L1 Positive Participants
percentage of participantsTislelizumab + ChemotherapyPlacebo + Chemotherapy
Disease Control Rate in PD-L1 Positive Participants88.3 (83.9 to 91.9)83.1 (78.1 to 87.3)
SecondaryDisease Control Rate in the ITT Analysis Set

Disease Control Rate is defined as the percentage of participants who had confirmed CR, PR, or stable disease (SD) assessed by the investigator per RECIST v1.1. Investigators conducted assessments of radiological tumor response by CT or MRI per RECIST version 1.1 about every six weeks during the first 48 weeks of the study and every nine weeks thereafter. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits. SD: Neither sufficient shrinkage in size of lesions to qualify for PR nor sufficient increase to qualify for PD, and no new lesions.

Time frame:
Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Reported as:
Number · percentage of participants
Disease Control Rate in the ITT Analysis Set
percentage of participantsTislelizumab + ChemotherapyPlacebo + Chemotherapy
Disease Control Rate in the ITT Analysis Set89.8 (86.8 to 92.3)83.3 (79.7 to 86.4)
SecondaryClinical Benefit Rate (CBR) in PD-L1 Positive Participants

Clinical benefit rate is defined as the percentage of participants who achieved a confirmed complete response, partial response, or durable stable disease assessed by the Investigator per RECIST v1.1. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits. Durable SD: Stable disease for ≥ 24 weeks.

Time frame:
Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR) in PD-L1 Positive Participants
percentage of participantsTislelizumab + ChemotherapyPlacebo + Chemotherapy
Clinical Benefit Rate (CBR) in PD-L1 Positive Participants65.0 (59.0 to 70.6)59.2 (53.1 to 65.1)
SecondaryClinical Benefit Rate (CBR) in the ITT Analysis Set

Clinical benefit rate is defined as the percentage of participants who achieved a confirmed complete response, partial response, or durable stable disease assessed by the Investigator per RECIST v1.1. CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits. Durable SD: Stable disease for ≥ 24 weeks.

Time frame:
Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR) in the ITT Analysis Set
percentage of participantsTislelizumab + ChemotherapyPlacebo + Chemotherapy
Clinical Benefit Rate (CBR) in the ITT Analysis Set63.1 (58.7 to 67.3)58.9 (54.4 to 63.2)
SecondaryTime to Response (TTR) in PD-L1 Positive Participants

Time to response is defined as the time from randomization to the first determination of an objective response per RECIST version 1.1 as assessed by the investigator.

Time frame:
From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Reported as:
Median · months
Time to Response (TTR) in PD-L1 Positive Participants
monthsTislelizumab + ChemotherapyPlacebo + Chemotherapy
Time to Response (TTR) in PD-L1 Positive Participants1.4 (0.9 to 11.3)1.4 (1.0 to 17.5)
SecondaryTime to Response (TTR) in the ITT Analysis Set

Time to response is defined as the time from randomization to the first determination of an objective response per RECIST version 1.1 as assessed by the investigator.

Time frame:
From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Reported as:
Median · months
Time to Response (TTR) in the ITT Analysis Set
monthsTislelizumab + ChemotherapyPlacebo + Chemotherapy
Time to Response (TTR) in the ITT Analysis Set1.4 (0.9 to 13.4)1.4 (1.0 to 17.5)

Adverse events

Collected over From first dose of study drug to 30 days after last dose or the initiation of a new anticancer therapy, whichever occurred first, up to the end of study; maximum treatment duration was 59.3 months in Tislelizumab and 56.8 months in the Placebo group.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tislelizumab + Chemotherapy397/501 (79.2%)211/498 (42.4%)489/498 (98.2%)
Placebo + Chemotherapy431/496 (86.9%)179/494 (36.2%)485/494 (98.2%)
Most frequent serious events
Showing 10 of 225
Most frequent serious events
EventTislelizumab + ChemotherapyPlacebo + Chemotherapy
Platelet count decreasedInvestigations16/49817/494
PneumoniaInfections and infestations12/49814/494
AnaemiaBlood and lymphatic system disorders4/49810/494
DeathGeneral disorders10/4985/494
Upper gastrointestinal haemorrhageGastrointestinal disorders4/4987/494
General physical health deteriorationGeneral disorders6/4987/494
VomitingGastrointestinal disorders7/4985/494
Decreased appetiteMetabolism and nutrition disorders7/4985/494
PyrexiaGeneral disorders6/4986/494
DiarrhoeaGastrointestinal disorders6/4984/494
Most frequent other events
Showing 10 of 72
Most frequent other events
EventTislelizumab + ChemotherapyPlacebo + Chemotherapy
NauseaGastrointestinal disorders248/498237/494
Decreased appetiteMetabolism and nutrition disorders202/498207/494
AnaemiaBlood and lymphatic system disorders197/498202/494
Platelet count decreasedInvestigations173/498184/494
VomitingGastrointestinal disorders176/498178/494
Neutrophil count decreasedInvestigations172/498163/494
Aspartate aminotransferase increasedInvestigations157/498150/494
DiarrhoeaGastrointestinal disorders134/498144/494
White blood cell count decreasedInvestigations120/498136/494
Alanine aminotransferase increasedInvestigations123/498105/494

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Tislelizumab + ChemotherapyPlacebo + ChemotherapyTotal
<=18 years000
Between 18 and 65 years340313653
>=65 years161183344
Age, Continuous
Age, Continuous(years)Tislelizumab + ChemotherapyPlacebo + ChemotherapyTotal
Mean58.8 ± 11.0759.7 ± 11.2059.3 ± 11.14
Sex: Female, Male
Sex: Female, Male(Participants)Tislelizumab + ChemotherapyPlacebo + ChemotherapyTotal
Female155150305
Male346346692
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tislelizumab + ChemotherapyPlacebo + ChemotherapyTotal
Hispanic or Latino268
Not Hispanic or Latino492474966
Unknown or Not Reported71623
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tislelizumab + ChemotherapyPlacebo + ChemotherapyTotal
Asian376372748
White116107223
Not Reported81624
Other101
Unknown011
Geographic Region
Geographic Region(Participants)Tislelizumab + ChemotherapyPlacebo + ChemotherapyTotal
China (including Taiwan)259257516
Japan and South Korea117115232
North America/Europe125124249
Primary Tumor Location
Primary Tumor Location(Participants)Tislelizumab + ChemotherapyPlacebo + ChemotherapyTotal
Stomach405395800
Gastro-oesophageal junction96100196
Other*011
PD-L1 Expression
PD-L1 Expression(Participants)Tislelizumab + ChemotherapyPlacebo + ChemotherapyTotal
< 5%227224451
≥ 5%274272546

2 further baseline measures are reported on the registry.

08

Study locations

149 sites
  • University of California Davis Health System
    Sacramento, California 95817, United States
  • Southeastern Regional Medical Center
    Newnan, Georgia 30265, United States
  • Ohio State University Hospital
    Columbus, Ohio 43210, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Reading Hospital
    West Reading, Pennsylvania 19611, United States
  • Tennessee Oncology, Pllc Nashville
    Nashville, Tennessee 37203, United States
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui 233004, China
  • Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital
    Hefei, Anhui 230088, China
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
  • Peking University Third Hospital
    Beijing, Beijing 100000, China
  • Beijing Chao Yang Hospital
    Beijing, Beijing 100020, China
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing 100050, China
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
  • Peking Union Medical College Hospital
    Beijing, Beijing 100730, China
  • Chinese Pla General Hospital
    Beijing, Beijing 100853, China
  • Beijing Luhe Hospital, Capital Medical University
    Beijing, Beijing 101149, China
  • Daping Hospital, Third Military Medical University
    Chongqing, Chongqing 400042, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350005, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
  • The First Hospital of Lanzhou University
    Lanzhou, Gansu 730000, China
  • Foshan First Peoples Hospital
    Foshan, Guangdong 528000, China
  • Sun Yat Sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Guangdong Provincial Peoples Hospital
    Guangzhou, Guangdong 510080, China
  • Shenzhen Peoples Hospital
    Shenzhen, Guangdong 518020, China
  • Affiliated Hospital of Guilin Medical University
    Guilin, Guangxi 541001, China
  • Hainan General Hospital
    Haikou, Hainan 570206, China
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050011, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • Henan Provincial Peoples Hospital
    Zhengzhou, Henan 450003, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan 410008, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School
    Nanjing, Jiangsu 210008, China
  • Nantong Tumor Hospital Branch South
    Nantong, Jiangsu 226000, China
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
  • The General Hospital of Shenyang Military
    Shenyang, Liaoning 110016, China
  • Liaoning Cancer Hospital and Institute
    Shenyang, Liaoning 110042, China
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
  • Linyi Cancer Hospital
    Linyi, Shandong 276001, China
  • The Affiliated Hospital of Qingdao University Branch South
    Qingdao, Shandong 266000, China
  • Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai 200025, China
  • Affiliated Zhongshan Hospital of Fudan University
    Shanghai, Shanghai 200032, China
  • Shanghai General Hospital
    Shanghai, Shanghai 200080, China
  • Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai 200092, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin 300052, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin 300060, China
  • Yunnan Cancer Hospital
    Kunming, Yunnan 650100, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
  • Zhejiang University College of Medicine Second Affiliated Hospital
    Hangzhou, Zhejiang 310009, China
  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310016, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
  • Centre Georges Francois Leclerc
    Dijon, 21079, France
  • Chu Besancon Hopital Jean Minjoz
    Doubs, 25030, France
  • Hopital de La Timone
    Marseille, 13005, France
  • Icl Alexis Vautrin
    Meurthe Et Moselle, 54519, France
  • Hopital Nord Franche Comte Site Du Mittan
    Montbeliard, 25200, France
  • Centre Antoine Lacassagne
    Nice, 06100, France
  • Chu Bordeaux Hopital Haut Leveque
    Pessac, 33600, France
  • Azienda Ospedaliera Universitaria Policlinico Santorsola Malpighi
    Bologna, 40138, Italy
  • Fondazione Irccs Istituto Nazionale Dei Tumori
    Milano, 20133, Italy
  • Istituto Nazionale Tumori Fondazione G Pascale
    Napoli, 80131, Italy
  • Iov Istituto Oncologico Veneto Irccs
    Padova, 35128, Italy
  • Ao Ospedali Riuniti Marche Nord
    Pesaro, 61122, Italy
  • Azienda Ospedaliero Universitaria Pisana
    Pisa, 56126, Italy
  • Azienda Ospedaliera Universitaria Policlinico Tor Vergata
    Roma, 133, Italy
  • Irccs Ospedale Casa Sollievo Della Sofferenza
    San Giovanni Rotondo, 71013, Italy
  • Aou Senese Policlinico Santa Maria Alle Scotte
    Siena, 53100, Italy
  • Azienda Ospedaliera Citta Della Salute E Della Scienza Di Torino
    Torino, 10126, Italy
  • Azienda Ospedaliera Universitaria Delle Marche
    Torrette, 60020, Italy
  • Chiba Cancer Center
    Chibashi, Chiba 260-8717, Japan
  • Tesshokai Kameda General Hospital
    Kamogawashi, Chiba 296-8602, Japan
  • Nho Shikoku Cancer Center
    Matsuyamashi, Ehime 791-0280, Japan
  • Nho Kyushu Cancer Center
    Fukuokashi, Fukuoka 811-1395, Japan
  • Gunma Prefectural Cancer Center
    Otashi, Gunma 373-8550, Japan
  • Hokkaido University Hospital
    Sapporoshi, Hokkaido 060-8648, Japan
  • Johas Kansai Rosai Hospital
    Amagasakishi, Hyogo 660-8511, Japan
  • Ishikawa Prefectural Central Hospital
    Kanazawashi, Ishikawa 920-8530, Japan
  • Kagawa University Hospital
    Kitagun, Kagawa 761-0793, Japan
  • Kanagawa Cancer Center
    Yokohamashi, Kanagawa 241-8515, Japan
  • Oita University Hospital
    Yufushi, Oita 879-5593, Japan
  • Kurashiki Central Hospital
    Kurashikishi, Okayama 710-8602, Japan
  • Okayama University Hospital
    Okayamashi, Okayama 700-8558, Japan
  • Izumi City General Hospital
    Izumishi, Osaka 594-0073, Japan
  • Nho Osaka National Hospital
    Osakashi, Osaka 540-0006, Japan
  • Osaka University Hospital
    Suitashi, Osaka 565-0871, Japan
  • Saitama Medical University International Medical Center
    Hidakashi, Saitama 350-1298, Japan
  • Saitama Cancer Center
    Kitaadachigun, Saitama 362-0806, Japan
  • Hamamatsu University School of Medicine, University Hospital
    Hamamatsushi, Shizuoka 431-3192, Japan
  • National Cancer Center Hospital
    Chuoku, Tokyo 104-0045, Japan
  • Tokyo Metropolitan Tama Medical Center
    Fuchushi, Tokyo 183-8524, Japan
  • Cancer Institute Hospital of Jfcr
    Kotoku, Tokyo 135-8550, Japan
  • Center Hospital of the National Center For Global Health and Medicine
    Shinjukuku, Tokyo 162-8655, Japan
  • National Cancer Center
    Goyangsi, Gyeonggi-do 10408, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnamsi, Gyeonggi-do 13620, Korea, Republic of

Showing the first 100 of 149 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Feb 2023, 50 months.

Results were first posted in Feb 2025, 1 year 11 months after primary completion. A results delay was requested in Feb 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2018
First posted
Dec 17, 2018
StartActual
Dec 13, 2018
Primary completionActual
Feb 28, 2023
CompletionActual
Aug 27, 2024
Results delay requested
Feb 5, 2024
Results first posted
Feb 14, 2025
Last update
Feb 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03777657
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Dec 17, 2018
Start date
Dec 13, 2018
Primary completion
Feb 28, 2023
Completion
Aug 27, 2024
Results posted
Feb 14, 2025
Last update
Feb 14, 2025

Study contacts

Jin Wang, MD
study director · BeiGene

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion